LuTran Pharmaceuticals
 | |
| Private | |
| ISIN | 🆔 |
| Industry | Healthcare |
| Founded 📆 | 2016 |
| Founder 👔 | |
| Headquarters 🏙️ | Silicon Valley, USA |
Area served 🗺️ | |
Key people | David Tran, President, Ronald Griffith, Director and CSO |
| Products 📟 | BioTechnology |
| Members | |
Number of employees | |
| 🌐 Website | www.lutran.com |
| 📇 Address | |
| 📞 telephone | |
LuTran is a pharmaceutical research company headquartered in Silicon Valley with the objective of discovering and developing novel medicines for debilitating viral and neurological diseases: from AIDS through biosafety level 4 viruses, including Ebola hemorrhagic fever and Alzheimer’s.[1]
History[edit]
LuTran was founded in 2016 and is directed by Ronald Griffith, Ph.D., the company’s Director and Chief Science Officer. He is a senior executive with over 30 years of experience in the complete drug development process with a focus on virology and neurological diseases. Ronald has published over 150 patents and publications.[2]
LuTran has multiple compounds in development against the viruses of HIV/AIDS, Ebola, RSV, VZV and Alzheimer’s. Drug discovery efforts focus on improving intrinsic potency through stronger hydrophobic synergies in the target receptor, consequently improving efficacy and enhancing safety through maximizing specific hydrophobic interactions.
References[edit]
- ↑ "LuTran Inc at Gust". Gust. Retrieved 2017-05-16.
- ↑ pubmeddev. "Griffith RC[Author] - PubMed - NCBI". www.ncbi.nlm.nih.gov. Retrieved 2017-05-28.
External links[edit]
This article "LuTran Pharmaceuticals" is from Wikipedia. The list of its authors can be seen in its historical. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
